Atricure Inc. Stock
Atricure Inc. Stock
We can see a decrease in the price for Atricure Inc.. Compared to yesterday it has lost -€0.400 (-1.650%).
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Atricure Inc..
As a result the target price of 43 € shows a very positive potential of 80.67% compared to the current price of 23.8 € for Atricure Inc..
Pros and Cons of Atricure Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | -1.650% | -3.200% | -6.202% | -60.968% | -28.824% | -60.968% | -56.396% |
| SI-BONE Inc | -1.790% | -0.909% | -16.794% | -16.794% | -35.503% | - | - |
| Lantheus Holdings Inc | -0.550% | -0.122% | 3.091% | -27.970% | 14.266% | -14.562% | - |
| Orasure Tech | -0.760% | -3.731% | -3.008% | -16.234% | 25.243% | -51.321% | -73.818% |
Comments
AtriCure (NASDAQ:ATRC) was given a new $55.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (NASDAQ:ATRC) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $54.00 price target on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (NASDAQ:ATRC) had its price target raised by analysts at JPMorgan Chase & Co. from $42.00 to $48.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
News
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
This medical device innovator for cardiac surgery reported an insider sale amid a year of negative total returns.
Doraiswamy Vinayak, Chief Scientific Officer of AtriCure (NASDAQ:ATRC), reported the
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?
Sven Wehrwein, a member of the Board of Directors at AtriCure (NASDAQ:ATRC), exercised 10,000 non-qualified stock options and immediately sold the underlying shares in derivative transactions on